BAM
MRNA icon

Belpointe Asset Management’s Moderna MRNA Stock Holding History

Belpointe Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Sell
32,598
-1,444
-4% -$74.7K 0.07% 243
2026
Q1 		$1.73M Buy
34,042
+25,827
+314% +$1.2M 0.06% 274
2025
Q4 		$242K Buy
8,215
+7
+0.1% +$190 0.01% 893
2025
Q3 		$212K Hold
8,208
– – 0.01% 914
2025
Q2 		$226K Buy
8,208
+15
+0.2% +$395 0.01% 841
2025
Q1 		$232K Buy
+8,193
New +$291K 0.01% 802
2024
Q4 		– Sell
-6,927
Closed -$463K – 918
2024
Q3 		$463K Buy
6,927
+4,865
+236% +$447K 0.03% 521
2024
Q2 		$245K Sell
2,062
-15,790
-88% -$2M 0.02% 658
2024
Q1 		$1.9M Buy
17,852
+2,587
+17% +$261K 0.14% 135
2023
Q4 		$1.52M Buy
15,265
+7,685
+101% +$646K 0.13% 155
2023
Q3 		$783K Buy
7,580
+5,346
+239% +$596K 0.08% 242
2023
Q2 		$271K Sell
2,234
-24,693
-92% -$3.29M 0.03% 490
2023
Q1 		$4.14M Sell
26,927
-4,417
-14% -$729K 0.22% 82
2022
Q4 		$5.63M Buy
31,344
+12,434
+66% +$2.03M 0.34% 50
2022
Q3 		$2.23M Buy
18,910
+13,928
+280% +$2.11M 0.15% 132
2022
Q2 		$711K Sell
4,982
-510
-9% -$72.9K 0.05% 379
2022
Q1 		$946K Buy
5,492
+328
+6% +$55.2K 0.06% 354
2021
Q4 		$1.31M Sell
5,164
-908
-15% -$265K 0.08% 247
2021
Q3 		$2.34M Sell
6,072
-1,580
-21% -$583K 0.16% 134
2021
Q2 		$1.8M Buy
7,652
+2,418
+46% +$432K 0.13% 170
2021
Q1 		$685K Sell
5,234
-877
-14% -$127K 0.06% 333
2020
Q4 		$639K Buy
6,111
+294
+5% +$29.7K 0.06% 343
2020
Q3 		$411K Sell
5,817
-2,027
-26% -$141K 0.05% 366
2020
Q2 		$504K Buy
+7,844
New +$430K 0.07% 304

Other funds holding MRNA

BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return

Belpointe Asset Management's MRNA Position: Q2 2026 in Review

Belpointe Asset Management reduced its Moderna (MRNA) stake by 4.2% in Q2 2026, selling an estimated $74.7K and leaving 32,598 shares worth $2.28M. The position accounts for 0.07% of the portfolio, ranked #243.

Belpointe Asset Management first reported a position in MRNA in Q2 2020 and has held it in 24 quarters since. The position peaked at $5.63M in Q4 2022. 283 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Belpointe Asset Management held 32,598 shares of Moderna worth $2.28M as of Q2 2026.
  • Belpointe Asset Management sold 1,444 Moderna shares in Q2 2026, an estimated $74.7K.
  • Moderna made up 0.07% of Belpointe Asset Management's portfolio in Q2 2026, its #243 holding.
  • Belpointe Asset Management first reported a position in Moderna in Q2 2020 and has held it in 24 quarters since.
  • Belpointe Asset Management's Moderna position peaked at $5.63M in Q4 2022.
  • 283 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.